RxDoctor Payments Data

Patricia Dempsey

Family · Asbury Park, NJNPI 1750336681

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 63 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$286
  • Viiv Healthcare Company$209
  • Gilead$142
  • Theratechnologies Inc.$113
  • Merck$79
  • Pfizer$70
  • plus $406 from 12 others

What the payments were for

  • Food & beverage$1,303100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,303 in reported general payments places this provider in the 80th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,697
Medicare patients
19
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate96$91,387
JardianceEmpagliflozin32$32,652
EliquisApixaban20$20,155
RybelsusSemaglutide13$12,621
JanumetSitagliptin Phos/Metformin Hcl14$11,438
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$10,755
Atrovent HfaIpratropium Bromide21$9,197
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$8,828
VascepaIcosapent Ethyl18$7,973
Fluticasone-SalmeterolFluticasone Propion/Salmeterol42$5,725
NexiumEsomeprazole Magnesium11$5,357
Combivent RespimatIpratropium/Albuterol Sulfate11$5,038
Incruse ElliptaUmeclidinium Bromide15$4,869
Pulmicort FlexhalerBudesonide20$4,523
Albuterol Sulfate HfaAlbuterol Sulfate158$4,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$79$102,825110 claims
PfizerEliquis$70$20,15520 claims
Novo NordiskRybelsus$34$12,62113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,692 family providers in New Jersey.

Other family in Asbury Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →